Zegerid Switch Progress Generates Bottom Line Help For Santarus

Santarus' OTC licensing of its Zegerid Rx heartburn remedy to Schering-Plough has yet to pay dividends for S-P, but the deal is already helping Santarus reduce its net loss

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet